TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up

Teva Pharmaceutical Industries (TEVA) reported second-quarter 2024 adjusted earnings of 61 cents per share, which beat the Zacks Consensus Estimate of 57 cents. Adjusted earnings rose 9% from 56 cents reported in the year-ago quarter. Revenues for the second quarter came in at $4.16 billion, which beat the Zacks Consensus Estimate of$3.99 billion. Total revenues rose 7% on a reported basis and 11% on a constant currency basis. Sales growth was mainly driven by higher revenues from generic products globally ...